Skip to main content

Atrys Health, a firm resulting from the merger between Althia and eDiagnostic, dedicated to providing diagnostic services and medical treatments, has issued new shares to a value of 4.5 million euros and has started trading on the Alternative Stock Market (MAB) with a market capitalization of 16.5 million euros.

The firm has captured 73 new investors, mainly family offices, and hopes that through raising 4.5 million euros the firm will be able to finance the opening of new radiotherapy centers, promote new diagnostic services and expand internationally.

Capital risk investment company Inveready is now the main shareholder, controlling 29% of the company’s shares, while the scientific and management team holds 27%. The remaining shareholding is held by family offices and institutional investors.

With its debut on the MAB, the firm expects to increase its visibility and strengthen its position against other financial institutions. As Santiago de Torres, the firm’s president, told Spanish newspaper La Vanguardia, the group does not envisage further financial rounds since the cash flow generated by the firm already allows it to finance its growth.

Atrys has completed the purchase of two new radiotherapy machines, investing 3.3 million euros, and it plans to buy four more in the coming months, the firm explained in the letter of introduction to the MAB. In addition, it is currently negotiating the purchase of a new diagnostic laboratory and is planning to begin operations in Colombia, where it has set up a firm with a local partner.  

Atrys Health, with its headquarters in Barcelona, is the result of the merger between Althia –a tissue diagnostics firm specializing in cancer, in which oncologist Carlos Cordón was involved– and eDiagnostic –a firm which provides remote diagnostic imaging services, headed by De Torres–. The two professionals continue to be involved in the firm. Atrys closed the financial year 2015 with a net profit of 1.3 million euros.


Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.